drugset
drugset / Trial / NCT05757531

A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants

NCT05757531 ↗

Phase 1 Completed 7 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The main purpose of this study is to is to look at how much LY3437943 gets into the bloodstream and how long the body takes to get rid of it in healthy male participants. This study will involve a single dose of 14C radiolabeled LY3437943. his means that a radioactive tracer substance, C14, will be incorporated into the study drug to investigate the study drug and its breakdown products and to find out how much of these pass from blood into urine, feces and expired air. The study will last up to approximately 15 weeks including the screening period of 28 days.

Timeline

Start
2023-03-17
Primary completion
2023-06-23
Completion
2023-06-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Retatrutide Protein / enzyme biologic — Subcutaneous

Indications

No indication recorded.